Ruvie Martin

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

Dominique Baeten, Joachim Sieper, Jürgen Braun et al. · New England Journal of Medicine · 2015 · 973 citations · Full text

MRI hyperintensities of the temporal lobe and external capsule in patients with CADASIL

Michael O’Sullivan, J. Jarosz, Ruvie Martin et al. · Neurology · 2001 · 356 citations

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial

Iain B. McInnes, Frank Behrens, Philip J. Mease et al. · The Lancet · 2020 · 271 citations · Full text

Rheumatology, Autoimmune Disease, Medicine +10

Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials

Alexa B. Kimball, Gregor B. E. Jemec, Afsáneh Alavi et al. · The Lancet · 2023 · 270 citations

Inflammation, Double-blind Phase 3, Week 16 +5

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study

Jürgen Braun, Xenofon Baraliakos, Atul Deodhar et al. · Annals of the Rheumatic Diseases · 2016 · 260 citations · Full text